Lion Street Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Lion Street Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-99	Closed	-$9K	–	441
2020 Q1	$9K	Buy	+99	New	+$9.72K	0.05%	182

Other funds holding ALXN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lion Street Advisors's ALXN Position: Q2 2020 in Review

Lion Street Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 99 shares — an estimated $9K sold.

Lion Street Advisors first reported a position in ALXN in Q1 2020 and held it in 1 quarter. The position peaked at $9K in Q1 2020. 705 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

Lion Street Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Lion Street Advisors sold 99 Alexion Pharmaceuticals shares in Q2 2020, an estimated $9K.
Lion Street Advisors first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 1 quarter.
Lion Street Advisors's Alexion Pharmaceuticals position peaked at $9K in Q1 2020.
705 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Lion Street Advisors's 13F filing for Q2 2020, filed 20 Jul 2020.